Heart rhythm · 2025
Cannabis use and atrial arrhythmias: A systematic review and meta-analysis of large populational studies.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chye David M, Sampaio Rodrigues Thalys, Quarto Levindo J G, Young Naomie, Hamilton Garry W, Burrell Louise M, Teh Andrew W, Lim Han S, Koshy Anoop N
Аннотация
BACKGROUND: Delta-9-tetrahydrocannabinol, a major component of cannabis, causes sympathetic stimulation and endothelial dysfunction. A recent American Heart Association consensus document has outlined cardiovascular risks associated with cannabis use. However, there are limited data surrounding atrial arrhythmias (AA).
OBJECTIVES: This study aimed to investigate the association between cannabis use and the risk of AAs.
METHODS: MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were searched for articles published up to April 2024 for studies on cannabis use and AAs (atrial fibrillation/flutter/tachycardia, supraventricular tachycardia). Odds ratios (OR) and 95% confidence intervals (CIs) were pooled using a random-effects model. The study was prospectively registered (PROSPERO CRD42023428219).
RESULTS: Fourteen observational studies were included with 81,230,930 participants from North America, Europe, and Oceania. Mean age was 47.2 years; 63.3% of participants were female. Five studies were prospective. AA was observed in 1.9% of participants (n = 1,578,033), that is, 12.5% of cannabis users (n = 90,195) and 2.7% of controls (n = 1,487,838). Cannabis was associated with a 71% increased risk of AAs (95% CI 1.1-2.6, P = .01). Factors associated with further increased AA risk included concomitant drug use (OR 1.91, 95% CI 1.1-3.5, P = .03) and consumption in cannabis-legal countries (OR 1.93, 95% CI 1.1-3.5, P = .03).
CONCLUSION: Cannabis use was associated with a 71% increased risk of AAs. A significant paucity of research in non-Western and teenage populations comprise key areas for future research to better inform public health and legalization policies.
OBJECTIVES: This study aimed to investigate the association between cannabis use and the risk of AAs.
METHODS: MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were searched for articles published up to April 2024 for studies on cannabis use and AAs (atrial fibrillation/flutter/tachycardia, supraventricular tachycardia). Odds ratios (OR) and 95% confidence intervals (CIs) were pooled using a random-effects model. The study was prospectively registered (PROSPERO CRD42023428219).
RESULTS: Fourteen observational studies were included with 81,230,930 participants from North America, Europe, and Oceania. Mean age was 47.2 years; 63.3% of participants were female. Five studies were prospective. AA was observed in 1.9% of participants (n = 1,578,033), that is, 12.5% of cannabis users (n = 90,195) and 2.7% of controls (n = 1,487,838). Cannabis was associated with a 71% increased risk of AAs (95% CI 1.1-2.6, P = .01). Factors associated with further increased AA risk included concomitant drug use (OR 1.91, 95% CI 1.1-3.5, P = .03) and consumption in cannabis-legal countries (OR 1.93, 95% CI 1.1-3.5, P = .03).
CONCLUSION: Cannabis use was associated with a 71% increased risk of AAs. A significant paucity of research in non-Western and teenage populations comprise key areas for future research to better inform public health and legalization policies.